HighTower Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

HighTower Advisors’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-43,000	Closed	-$139K	–	4027
2025 Q1	$139K	Buy	+43,000	New	+$188K	﹤0.01%	3286

Other funds holding TELO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

HighTower Advisors's TELO Position: Q2 2025 in Review

HighTower Advisors sold out of Telomir Pharmaceuticals (TELO) in Q2 2025, closing a stake of 43,000 shares — an estimated $139K sold.

HighTower Advisors first reported a position in TELO in Q1 2025 and held it in 1 quarter. The position peaked at $139K in Q1 2025. 43 funds tracked by Wall St. Rank hold TELO as of Q2 2025.

HighTower Advisors reported no remaining Telomir Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
HighTower Advisors sold 43,000 Telomir Pharmaceuticals shares in Q2 2025, an estimated $139K.
HighTower Advisors first reported a position in Telomir Pharmaceuticals in Q1 2025 and held it in 1 quarter.
HighTower Advisors's Telomir Pharmaceuticals position peaked at $139K in Q1 2025.
43 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2025.

Based on HighTower Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.